Literature DB >> 35460389

Clinical characteristics and outcomes of 100 adult patients with pure red cell aplasia.

Xuemei Wu1, Lang Cheng2, Xiaoqing Liu2, Yu Sun1, Bingzong Li1, Guangsheng He3, Jianyong Li2.   

Abstract

Adult pure red cell aplasia (PRCA) is a rare syndrome characterized by a severe normocytic anemia, reticulocytopenia, and absence of erythroblasts from bone marrow. The standard treatment has not yet been established for PRCA, although cyclosporine (CsA), corticosteroids (CS) showed a response in PRCA. We retrospectively analyzed the clinical data of 60 primary and 40 secondary adult patients with acquired PRCA. The proportion of secondary PRCA is relatively high and commonly associated with large granular lymphocyte leukemia (LGLL) (28 cases, 70.0%). The remission-induced regimens included CS, CsA, or other agents, and the response rate was 66.7%, 71.4%, and 50%, respectively (P = 0.336). When treating with CsA, the response rate of LGLL-associated PRCA was lower than primary PRCA (42.1% vs 85.7%, P = 0.001). Logistic regression analysis showed that ORR was inversely related to LGLL-associated PRCA. LGLL-associated PRCA had poor therapeutic efficacy to CsA.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cyclosporine A; Large granular lymphocytic leukemia; Pure red cell aplasia; Secondary

Mesh:

Substances:

Year:  2022        PMID: 35460389     DOI: 10.1007/s00277-022-04847-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  24 in total

1.  Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience.

Authors:  Carrie A Thompson; David P Steensma
Journal:  Br J Haematol       Date:  2006-11       Impact factor: 6.998

Review 2.  The biology of pure red cell aplasia.

Authors:  E N Dessypris
Journal:  Semin Hematol       Date:  1991-10       Impact factor: 3.851

3.  Response to cyclosporine A and corticosteroids in adult patients with acquired pure red cell aplasia: serial experience at a single center.

Authors:  Xuemei Wu; Suli Wang; Xingyu Lu; Wenyi Shen; Chun Qiao; Yujie Wu; Ruinan Lu; Shuai Wang; Jianfu Zhang; Ming Hong; Yu Zhu; Jianyong Li; Guangsheng He
Journal:  Int J Hematol       Date:  2018-03-27       Impact factor: 2.490

4.  Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia.

Authors:  J Rossignol; A-S Michallet; L Oberic; M Picard; A Garon; C Willekens; R Dulery; X Leleu; B Cazin; L Ysebaert
Journal:  Leukemia       Date:  2010-12-03       Impact factor: 11.528

Review 5.  Pure red cell aplasia.

Authors:  Robert T Means
Journal:  Blood       Date:  2016-11-24       Impact factor: 22.113

6.  Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA.

Authors:  Antonio Maria Risitano; Carmine Selleri; Bianca Serio; Giovanni Fernando Torelli; Alexander Kulagin; Sébastien Maury; Jörg Halter; Vikas Gupta; Andrea Bacigalupo; Gerard Sociè; André Tichelli; Hubert Schrezenmeier; Judith Marsh; Jakob Passweg; Bruno Rotoli
Journal:  Br J Haematol       Date:  2009-12-07       Impact factor: 6.998

7.  Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab.

Authors:  Elaine M Sloand; Matthew J Olnes; Barbara Weinstein; Colin Wu; Jaroslaw Maciejewski; Phillip Scheinberg; Neal S Young
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

8.  Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia.

Authors:  M Zecca; P De Stefano; B Nobili; F Locatelli
Journal:  Blood       Date:  2001-06-15       Impact factor: 22.113

9.  A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: response to rituximab and cyclophosphamide.

Authors:  R K Gupta; A N Ezeonyeji; A S Thomas; M A Scully; M R Ehrenstein; D A Isenberg
Journal:  Lupus       Date:  2011-10-12       Impact factor: 2.911

10.  Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group.

Authors:  Ken-ichi Sawada; Makoto Hirokawa; Naohito Fujishima; Masanao Teramura; Masami Bessho; Kazuo Dan; Hisashi Tsurumi; Shinji Nakao; Akio Urabe; Mitsuhiro Omine; Keiya Ozawa
Journal:  Haematologica       Date:  2007-07-20       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.